Clinical Trials Sponsored by Sebela Pharmaceuticals Development LLC

Total 44 results

Sebela Pharmaceuticals Development LLC

Completed

Safety and Efficacy Study of an Edible Colonoscopy Preparation

Colon Prep for Colonoscopy

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals; OSI Pharmaceuticals

Completed

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Terminated

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Small Cell Lung Cancer | Ovarian Cancer

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Completed

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

United States
Janssen Research & Development, LLC
Janssen Pharmaceuticals

Completed

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Influenza A

United States, Germany, Bulgaria, Canada, Estonia, Latvia, Belgium, Puerto Rico
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer

Breast Cancer
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Prostate Cancer

United States
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients

Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Completed

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Metastatic or Unresectable Solid Tumor Malignancy

United States
SCRI Development Innovations, LLC
Aventis Pharmaceuticals

Completed

Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer

Breast Cancer
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Terminated

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States
GE Healthcare
Pharmaceutical Product Development, LLC

Completed

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Coronary Artery Disease (CAD)

United States, Germany, Switzerland, Canada, Netherlands, France, Finland
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.; Aventis Pharmaceuticals

Completed

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

Prostate Cancer
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.

Completed

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.

Completed

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Infinity Pharmaceuticals, Inc.

Completed

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | T-cell Lymphoma

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; OSI Pharmaceuticals

Completed

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; Aventis Pharmaceuticals

Completed

Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

Breast Cancer
SCRI Development Innovations, LLC
AstraZeneca; Aventis Pharmaceuticals

Completed

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Head and Neck Cancer

United States
SCRI Development Innovations, LLC
Novartis; Aventis Pharmaceuticals

Completed

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer; OSI Pharmaceuticals

Completed

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

Non-Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.

Completed

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Multiple Myeloma

United States
Janssen Pharmaceutical K.K.
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64530440 in Healthy Japanese Male Participants

Healthy

Japan
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.; Cephalon

Completed

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Aventis Pharmaceuticals; Sanofi-Synthelabo

Completed

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Esophagus Cancer

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.; Celgene

Completed

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.; Cephalon

Completed

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Lymphoma

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; AstraZeneca; Aventis Pharmaceuticals

Completed

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Lung Cancer

United States
SCRI Development Innovations, LLC
Aventis Pharmaceuticals; Ortho Biotech, Inc.

Completed

Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Aventis Pharmaceuticals; Pharmacia and Upjohn

Terminated

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

Breast Cancer
Qure Healthcare, LLC
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Establishing Clinical Utility for a New Diagnostic Test for Patients With Shortness of Breath

Dyspnea | Unexplained Chronic Dyspnea

United States
Janssen-Ortho LLC
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

Migraine | Common Migraine | Classic Migraine
SCRI Development Innovations, LLC
Eli Lilly and Company; Aventis Pharmaceuticals

Completed

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States
Astellas Pharma Global Development, Inc.
Cubist Pharmaceuticals LLC

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects

Healthy Subjects | Pharmacokinetics of Fidaxomicin

United States
VA Office of Research and Development
Merck Sharp & Dohme LLC; Endo Pharmaceuticals

Completed

5-Alpha Reductase and Anabolic Effects of Testosterone

Sarcopenia | Muscle Atrophy | Male Hypogonadism | Benign Prostate Hypertrophy

United States
University of Virginia
Merck Sharp & Dohme LLC; Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

CTCL | PTCL

United States
SCRI Development Innovations, LLC
Eli Lilly and Company; Aventis Pharmaceuticals; Pharmacia and Upjohn

Completed

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Breast Cancer
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects

Type 2 Diabetes

United States
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Unknown

Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM

Type 2 Diabetes
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
Foundation for the National Institutes of Health
Eli Lilly and Company; National Institute of Diabetes and Digestive and Kidney... and other collaborators

Completed

Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes

Type 2 Diabetes

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaborators

Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (CRISP)

Small-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage II

Germany
US Department of Veterans Affairs
Bristol-Myers Squibb; Sanofi; GE Healthcare; Merck Sharp & Dohme LLC; Pfizer; Astra... and other collaborators

Completed

Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

Myocardial Ischemia

United States, Canada

Clinical Trials Sponsored by Sebela Pharmaceuticals Development LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations